Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre of Cancer Medicine, Guangzhou, Korea.
Department of Oncology, Pan Yu Central Hospital, Guangzhou, China.
Cancer Res Treat. 2019 Oct;51(4):1557-1567. doi: 10.4143/crt.2018.681. Epub 2019 Apr 1.
The extranodal natural killer (NK)/T-cell lymphoma (NKTCL) of non-upper aerodigestive tract (NUAT) was found to have clinical heterogeneity compared with NKTCL of the upper aerodigestive tract (UAT) in small scale studies. We conducted this study in a much larger cohort to analyze the clinical characteristics, prognostic factors, treatment modality, and clinical outcomes of patients with NUAT-NKTCL.
From January 2001 to December 2017, a total of 757 NKTCL patients were identified and included in this study, including 92 NUAT-NKTCL patients (12.2%) and 665 UAT-NKTCL patients (87.8%).
NUAT-NKTCL patients had relatively poorer performance status, more unfavorable prognostic factors, and more advanced stage, compared with UAT-NKTCL patients. The 5-year overall survival (OS) was 34.7% for NUAT-NKTCL, which was significantly worse than UAT-NKTCL (64.2%, p<0.001). The median OS duration was 30.9 months for NUAT-NKTCL. Multivariate analysis showed that presence with B symptoms and elevated serum lactate dehydrogenase independently predicted worse OS. International prognostic index score and prognostic index of natural killer lymphoma score still had prognostic values in NUAT-NKTCL, while the Ann Arbor system could not accurately predict the OS.
NUAT-NKTCL is a distinctive subtype of NKTCL in many aspects. Patients with NUAT-NKTCL have relatively poorer performance status, more unfavorable prognostic factors, more advanced stage, and poorer prognosis.
与上呼吸消化道(UAT)NK/T 细胞淋巴瘤(NKTCL)相比,非上呼吸消化道(NUAT)NKTCL 在小规模研究中表现出临床异质性。我们在更大的队列中进行了这项研究,以分析 NUAT-NKTCL 患者的临床特征、预后因素、治疗方式和临床结果。
从 2001 年 1 月至 2017 年 12 月,共确定了 757 例 NKTCL 患者,并将其纳入本研究,包括 92 例 NUAT-NKTCL 患者(12.2%)和 665 例 UAT-NKTCL 患者(87.8%)。
与 UAT-NKTCL 患者相比,NUAT-NKTCL 患者的一般状况较差,预后不良因素较多,分期较晚。NUAT-NKTCL 的 5 年总生存率(OS)为 34.7%,明显低于 UAT-NKTCL(64.2%,p<0.001)。NUAT-NKTCL 的中位 OS 时间为 30.9 个月。多因素分析表明,B 症状和血清乳酸脱氢酶升高与 OS 不良独立相关。国际预后指数评分和自然杀伤淋巴瘤评分预后指数在 NUAT-NKTCL 中仍具有预后价值,而 Ann Arbor 系统不能准确预测 OS。
NUAT-NKTCL 在许多方面都是一种独特的 NKTCL 亚型。与 UAT-NKTCL 相比,NUAT-NKTCL 患者的一般状况较差,预后不良因素较多,分期较晚,预后较差。